trifluoroacetyl chloride: anesthetics are believed to trigger hepatitis by covalently linking a trifluoroacetyl (TFA) chloride hapten to hepatic proteins, forming haptenated self-proteins [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 61106 |
| CHEBI ID | 29138 |
| SCHEMBL ID | 1810 |
| MeSH ID | M0484655 |
| Synonym |
|---|
| un3057 |
| einecs 206-556-2 |
| cf3cocl |
| perfluoroacetyl chloride |
| CHEBI:29138 |
| 354-32-5 |
| 2,2,2-trifluoroacetyl chloride |
| trifluoroacetyl chloride |
| trifluoroacetyl chloride, 98% |
| acetyl chloride, trifluoro- |
| acetyl chloride, 2,2,2-trifluoro- |
| hsdb 8401 |
| a23u71sy9g , |
| trifluoroacetyl chloride [un3057] [poison] |
| unii-a23u71sy9g |
| ec 206-556-2 |
| FT-0632023 |
| AKOS015912430 |
| FD2059 |
| SCHEMBL1810 |
| trifluoroacetylchloride |
| DTXSID1029176 |
| mfcd00039307 |
| trifluoroacetyl chloride 99% |
| Q2453085 |
| AMY3623 |
| Class | Description |
|---|---|
| acyl chloride | A compound consisting of an acyl group bonded to chlorine. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Biological oxidations | 150 | 276 |
| Phase I - Functionalization of compounds | 69 | 175 |
| Cytochrome P450 - arranged by substrate type | 30 | 110 |
| Xenobiotics | 4 | 50 |
| CYP2E1 reactions | 0 | 19 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||